Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation
Contributeurs/tricesGerbase, Margaret; Dubois, D; Rothmeier, Claudia
Publié dansChest, vol. 116, no. 5, p. 1265-1272
Date de publication1999
Résumé
Mots-clés
- Adolescent
- Adult
- Antibiotic Prophylaxis/economics/methods
- Antibodies, Viral/analysis
- Antiviral Agents/administration & dosage/economics/therapeutic use
- Bronchoalveolar Lavage Fluid/virology
- Child
- Cost-Benefit Analysis
- Costs and Cost Analysis
- Cytomegalovirus/immunology/isolation & purification
- Cytomegalovirus Infections/economics/epidemiology/prevention & control/virology
- Female
- Follow-Up Studies
- Ganciclovir/administration & dosage/economics/therapeutic use
- Graft Rejection/immunology/prevention & control
- Humans
- Immunosuppressive Agents/therapeutic use
- Incidence
- Infusions, Intravenous
- Lung Transplantation
- Male
- Middle Aged
- Pneumonia, Viral/economics/epidemiology/prevention & control/virology
- Prospective Studies
- Survival Rate
- Switzerland/epidemiology
- Treatment Outcome
Structure d'affiliation
Citation (format ISO)
GERBASE, Margaret et al. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. In: Chest, 1999, vol. 116, n° 5, p. 1265–1272. doi: 10.1378/chest.116.5.1265
Fichiers principaux (1)
Article (Published version)
Identifiants
- PID : unige:72647
- DOI : 10.1378/chest.116.5.1265
- PMID : 10559085
ISSN du journal0012-3692
